MetaVia Appoints Seasoned Clinical Development Executive Sarah Browne, M.D., as Chief Medical Officer
Key Highlights
- ➤Sarah Browne appointed MetaVia (MTVA) Chief Medical Officer, effective October 12, 2026
- ➤Browne brings over 20 years’ clinical development, regulatory, and medical experience
- ➤DA-1726 Phase 1 Part 3 topline data readout anticipated in fourth quarter 2026
- ➤Browne previously advanced pemvidutide through Phase 2 and established Phase 3 strategies
- ➤Vanoglipel (DA-1241) is being developed for MASH treatment
Expert Statements
Hyung Heon Kim, President and Chief Executive Officer of MetaVia
“Sarah brings an exceptional combination of clinical development leadership and regulatory expertise, particularly in advancing novel therapies for liver and other cardiometabolic diseases, including MASH”
Hyung Heon Kim, President and Chief Executive Officer of MetaVia
“Her extensive experience leading the clinical development of pemvidutide, a dual GLP-1/glucagon receptor agonist, through Phase 2 and establishing Phase 3 development strategies, will be invaluable as we plan the next stages of development for DA-1726.”
Hyung Heon Kim, President and Chief Executive Officer of MetaVia
“Sarah joins MetaVia at an important time as we prepare for the anticipated fourth quarter 2026 topline data readout from Part 3 of our Phase 1 clinical trial of DA-1726, evaluating higher target doses of 48 mg and 64 mg.”
Hyung Heon Kim, President and Chief Executive Officer of MetaVia
“We look forward to leveraging her expertise as we continue advancing our cardiometabolic pipeline, including DA-1726 and vanoglipel (DA-1241), which is being developed for the treatment of MASH.”
Sarah Browne, M.D., Chief Medical Officer of MetaVia
“MetaVia is approaching a key inflection point in the development of DA-1726.”
Sarah Browne, M.D., Chief Medical Officer of MetaVia
“My experience developing therapies for obesity and liver disease, including dual GLP-1/glucagon receptor agonists, aligns closely with MetaVia's clinical programs.”
Sarah Browne, M.D., Chief Medical Officer of MetaVia
“I look forward to working with the team to evaluate the upcoming Phase 1 Part 3 results, help shape the next stages of development for DA-1726, and advancing vanoglipel for the treatment of MASH.”
Sarah Browne, M.D., Chief Medical Officer of MetaVia
“I believe these programs have the potential to address significant unmet medical needs across cardiometabolic diseases.”
MetaVia Appoints Seasoned Clinical Development Executive Sarah Browne, M.D., as Chief Medical Officer PR Newswire
Brings Extensive Experience Leading Liver and Metabolic Disease Drug Development Programs, Including MASH, and Successfully Advancing Therapies Through Phase 2 and Into Phase 3 Development
Get started
Create a free account to read the full story.